The FDA accepted a New Drug Application to support the combination of the MEK inhibitor, binimetinib, and the BRAF inhibitor, encorafenib, for treating patients with BRAF-mutated unresectable or metastatic melanoma.
Hydrochlorothiazide use is associated with an increased risk of non-melanoma skin cancer, with evidence of a dose-response relationship.
Fluorouracil application can reduce the risk of surgery for squamous cell carcinoma for 1 year among patients with a history of keratinocyte carcinomas.
Laser monotherapy improves health-related quality of life in female patients with radiation-induced breast telangiectasias.
Pembrolizumab leads to a durable complete response with low rates of relapse — even 2 years after discontinuation — and may cure a subset of patients with metastatic melanoma.
The FDA has approved an adjuvant treatment for patients with melanoma with lymph node involvement or metastatic disease who have undergone complete resection.
Patients presenting with lesions with shiny white streaks on dermoscopy should undergo biopsy for possible melanoma.
Diligent Skin Cancer Screenings May Help Manage Squamous Cell Carcinoma Risk in Solid Organ Transplant Recipients
Transplant recipients developed squamous cell carcinomas that did not appear to behave more aggressively than those that developed in the immunocompetent group.
Researchers examined the changes in levels of different proteins in cancer cell lines after treatment with melatonin analogues
Dermatology Advisor Articles
- Specific Oral Bacteria May Reduce Risk for Squamous Cell Carcinoma
- Ostomy-Related Costs Reduced With Ceramide-Infused Skin Barrier
- Pediatric Psoriasis Associated With Increased Risk for Comorbidity Development
- Improved Neck, Décolletage Lines With Ultrasound, Diluted Calcium Hydroxylapatite
- New Nutrition Science Course Available for Physicians